CLAIMS:

1. An T-cell receptor (TCR) comprising the amino acid sequences of:

(a) all of SEQ ID NOs: 1-6,

(b) all of SEQ ID NOs: 31-36, or

(c) all of SEQ ID NOs: 64-69,

wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence presented by a human leukocyte antigen (HLA)-C molecule,

wherein the mutated human RAS amino acid sequence is a mutated human Kirsten rat sarcoma viral oncogene homolog (KRAS), a mutated human Harvey rat sarcoma viral oncogene homolog (HRAS), or a mutated human Neuroblastoma rat sarcoma viral oncogene homolog (NRAS) amino acid sequence,

wherein the mutated human RAS amino acid sequence has a substitution of glycine at position 12 with valine, and

wherein position 12 is defined by reference to the wild-type human KRAS, wild-type human HRAS, or wild-type human NRAS protein, respectively.

2. The TCR according to claim 1, wherein the HLA-C molecule is an HLA-C*01:02 molecule.

3. The TCR according to claim 1 or 2, comprising:

(i) the amino acid sequence of SEQ ID NO: 7;

(ii) the amino acid sequence of SEQ ID NO: 8;

(iii) the amino acid sequence of SEQ ID NO: 90;

(iv) the amino acid sequence of SEQ ID NO: 91;

(v) the amino acid sequence of SEQ ID NO: 37;

(vi) the amino acid sequence of SEQ ID NO: 38;

(vii) the amino acid sequence of SEQ ID NO: 92;

(viii) the amino acid sequence of SEQ ID NO: 93;

(ix) the amino acid sequence of SEQ ID NO: 70;

(x) the amino acid sequence of SEQ ID NO: 71;

(xi) the amino acid sequence of SEQ ID NO: 132;

(xii) the amino acid sequence of SEQ ID NO: 133;

(xiii) the amino acid sequence of SEQ ID NO: 47;

(xiv) the amino acid sequence of SEQ ID NO: 48;

(xv) the amino acid sequence of SEQ ID NO: 94;

(xvi) the amino acid sequence of SEQ ID NO: 85;

(xvii) the amino acid sequence of SEQ ID NO: 95;

(xviii) the amino acid sequence of SEQ ID NO: 49;

(xix) the amino acid sequence of SEQ ID NO: 50;

(xx) the amino acid sequence of SEQ ID NO: 96;

(xxi) the amino acid sequence of SEQ ID NO: 87;

(xxii) the amino acid sequence of SEQ ID NO: 97;

(xxiii) the amino acid sequence of SEQ ID NO: 72;

(xxvi) the amino acid sequence of SEQ ID NO: 73;

(xxv) the amino acid sequence of SEQ ID NO: 88;

(xxvi) the amino acid sequence of SEQ ID NO: 89; or

(xxvii) both (i) and (ii), both (i) and (iv), both (ii) and (iii), both (iii) and (iv), both (v) and (vi), both (v) and (viii), both (vi) and (vii), both (vii) and (viii), both (ix) and (x), both (ix) and (xii), both (x) and (xi), both (xi) and (xii), both (xiii) and (xiv), both (xiii) and (xvi), both (xiii) and (xvii), both (xiv) and (xv), both (xv) and (xvi), both (xv) and (xvii), both (xviii) and (xix), both (xviii) and (xxi), both (xviii) and (xxii), both (xix) and (xx), both (xx) and (xxi), both (xx) and (xxii), both (xxiii) and (xxiv), both (xxiii) and (xxvi), both (xxiv) and (xxv), or both (xxv) and (xxvi).

4. The TCR according to any one of claims 1-3, further comprising:

(a) an α chain constant region comprising the amino acid sequence of SEQ ID NO: 17, wherein:

(i) X at position 48 of SEQ ID NO: 17 is Thr or Cys;

(ii) X at position 112 of SEQ ID NO: 17 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 of SEQ ID NO: 17 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 115 of SEQ ID NO: 17 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain constant region comprising the amino acid sequence of SEQ ID NO: 18, wherein X at position 57 of SEQ ID NO: 18 is Ser or Cys; or

(c) both (a) and (b).

5. The TCR according to any one of claims 1-4, comprising:

(a) an α chain comprising the amino acid sequence of SEQ ID NO: 21, wherein:

(i) X at position 180 of SEQ ID NO: 21 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 21 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 21 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 21 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain comprising the amino acid sequence of SEQ ID NO: 22, wherein X at position 190 of SEQ ID NO: 22 is Ser or Cys;

(c) an α chain comprising the amino acid sequence of SEQ ID NO: 100, wherein:

(i) X at position 180 of SEQ ID NO: 100 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 100 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 100 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 100 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(d) a β chain comprising the amino acid sequence of SEQ ID NO: 101, wherein X at position 190 of SEQ ID NO: 101 is Ser or Cys;

(e) an α chain comprising the amino acid sequence of SEQ ID NO: 41, wherein:

(i) X at position 181 of SEQ ID NO: 41 is Thr or Cys;

(ii) X at position 245 of SEQ ID NO: 41 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 247 of SEQ ID NO: 41 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 248 of SEQ ID NO: 41 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(f) a β chain comprising the amino acid sequence of SEQ ID NO: 42, wherein X at position 195 of SEQ ID NO: 42 is Ser or Cys;

(g) an α chain comprising the amino acid sequence of SEQ ID NO: 106, wherein:

(i) X at position 181 of SEQ ID NO: 106 is Thr or Cys;

(ii) X at position 245 of SEQ ID NO: 106 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 247 of SEQ ID NO: 106 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 248 of SEQ ID NO: 106 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(h) a β chain comprising the amino acid sequence of SEQ ID NO: 107, wherein X at position 195 of SEQ ID NO: 107 is Ser or Cys;

(i) an α chain comprising the amino acid sequence of SEQ ID NO: 74, wherein:

(i) X at position 180 of SEQ ID NO: 74 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 74 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 74 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 74 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(j) a β chain comprising the amino acid sequence of SEQ ID NO: 75, wherein X at position 187 of SEQ ID NO: 75 is Ser or Cys;

(k) an α chain comprising the amino acid sequence of SEQ ID NO: 136, wherein:

(i) X at position 180 of SEQ ID NO: 136 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 136 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 136 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 136 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(l) a β chain comprising the amino acid sequence of SEQ ID NO: 137, wherein X at position 187 of SEQ ID NO: 75 is Ser or Cys;

(m) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d);

(n) both (e) and (f); both (e) and h); both (f) and (g); or both (g) and (h);

(n) both (i) and (j); both (i) and l); both (j) and (k); or both (k) and (l);

(o) an α chain comprising the amino acid sequence of SEQ ID NO: 55, wherein:

(i) X at position 160 of SEQ ID NO: 55 is Thr or Cys;

(ii) X at position 224 of SEQ ID NO: 55 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 226 of SEQ ID NO: 55 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 227 of SEQ ID NO: 55 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(p) a β chain comprising the amino acid sequence of SEQ ID NO: 56, wherein X at position 168 of SEQ ID NO: 56 is Ser or Cys;

(q) an α chain comprising the amino acid sequence of SEQ ID NO: 112, wherein:

(i) X at position 159 of SEQ ID NO: 112 is Thr or Cys;

(ii) X at position 223 of SEQ ID NO: 112 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 225 of SEQ ID NO: 112 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 226 of SEQ ID NO: 112 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(r) a β chain comprising the amino acid sequence of SEQ ID NO: 113, wherein X at position 173 of SEQ ID NO: 113 is Ser or Cys;

(s) an α chain comprising the amino acid sequence of SEQ ID NO: 57, wherein:

(i) X at position 160 of SEQ ID NO: 57 is Thr or Cys;

(ii) X at position 224 of SEQ ID NO: 57 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 226 of SEQ ID NO: 57 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 227 of SEQ ID NO: 57 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(t) a β chain comprising the amino acid sequence of SEQ ID NO: 58, wherein X at position 173 of SEQ ID NO: 58 is Ser or Cys;

(u) an α chain comprising the amino acid sequence of SEQ ID NO: 118, wherein:

(i) X at position 161 of SEQ ID NO: 118 is Thr or Cys;

(ii) X at position 225 of SEQ ID NO: 118 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 227 of SEQ ID NO: 118 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 228 of SEQ ID NO: 118 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(v) a β chain comprising the amino acid sequence of SEQ ID NO: 119, wherein X at position 178 of SEQ ID NO: 119 is Ser or Cys;

(w) an α chain comprising the amino acid sequence of SEQ ID NO: 76, wherein:

(i) X at position 159 of SEQ ID NO: 76 is Thr or Cys;

(ii) X at position 223 of SEQ ID NO: 76 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 225 of SEQ ID NO: 76 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 226 of SEQ ID NO: 76 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(x) a β chain comprising the amino acid sequence of SEQ ID NO: 77, wherein X at position 168 of SEQ ID NO: 77 is Ser or Cys;

(y) an α chain comprising the amino acid sequence of SEQ ID NO: 144, wherein:

(i) X at position 160 of SEQ ID NO: 144 is Thr or Cys;

(ii) X at position 224 of SEQ ID NO: 144 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 226 of SEQ ID NO: 144 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 227 of SEQ ID NO: 144 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(z) a β chain comprising the amino acid sequence of SEQ ID NO: 145, wherein X at position 166 of SEQ ID NO: 145 is Ser or Cys;

(aa) both (o) and (p); or both (q) and (r);

(bb) both (s) and (t); or both (u) and (v);

(cc) both (w) and (x); or both (y) and (z);

(dd) an α chain comprising the amino acid sequence of SEQ ID NO: 51;

(ee) a β chain comprising the amino acid sequence of SEQ ID NO: 52;

(ff) an α chain comprising the amino acid sequence of SEQ ID NO: 114;

(gg) a β chain comprising the amino acid sequence of SEQ ID NO: 115;

(hh) an α chain comprising the amino acid sequence of SEQ ID NO: 128;

(ii) a β chain comprising the amino acid sequence of SEQ ID NO: 129;

(jj) an α chain comprising the amino acid sequence of SEQ ID NO: 116;

(kk) a β chain comprising the amino acid sequence of SEQ ID NO: 117;

(ll) an α chain comprising the amino acid sequence of SEQ ID NO: 53;

(mm) a β chain comprising the amino acid sequence of SEQ ID NO: 54;

(nn) an α chain comprising the amino acid sequence of SEQ ID NO: 120;

(oo) a β chain comprising the amino acid sequence of SEQ ID NO: 121;

(pp) an α chain comprising the amino acid sequence of SEQ ID NO: 130;

(qq) a β chain comprising the amino acid sequence of SEQ ID NO: 131;

(rr) an α chain comprising the amino acid sequence of SEQ ID NO: 122;

(ss) a β chain comprising the amino acid sequence of SEQ ID NO: 123;

(tt) an α chain comprising the amino acid sequence of SEQ ID NO: 80;

(uu) a β chain comprising the amino acid sequence of SEQ ID NO: 81;

(vv) an α chain comprising the amino acid sequence of SEQ ID NO: 146;

(ww) a β chain comprising the amino acid sequence of SEQ ID NO: 146;

(xx) an α chain comprising the amino acid sequence of SEQ ID NO: 142;

(yy) a β chain comprising the amino acid sequence of SEQ ID NO: 143;

(zz) an α chain comprising the amino acid sequence of SEQ ID NO: 148;

(aaa) a β chain comprising the amino acid sequence of SEQ ID NO: 149;

(bbb) both (dd) and (ee); both (ff) and (gg); both (hh) and (ii); or both (jj) and (kk);

(ccc) both (ll) and (mm); both (nn) and (oo); both (pp) and (qq); or both (rr) and (ss);

(ddd) both (tt) and (uu); both (vv) and (ww); both (xx) and (yy); or both (zz) and (aaa);

(eee) an α chain comprising the amino acid sequence of SEQ ID NO: 23;

(fff) a β chain comprising the amino acid sequence of SEQ ID NO: 24;

(ggg) an α chain comprising the amino acid sequence of SEQ ID NO: 102;

(hhh) a β chain comprising the amino acid sequence of SEQ ID NO: 103;

(iii) an α chain comprising the amino acid sequence of SEQ ID NO: 124;

(jjj) a β chain comprising the amino acid sequence of SEQ ID NO: 125;

(kkk) an α chain comprising the amino acid sequence of SEQ ID NO: 104;

(lll) a β chain comprising the amino acid sequence of SEQ ID NO: 105;

(mmm) an α chain comprising the amino acid sequence of SEQ ID NO: 39;

(nnn) a β chain comprising the amino acid sequence of SEQ ID NO: 40;

(ooo) an α chain comprising the amino acid sequence of SEQ ID NO: 108;

(ppp) a β chain comprising the amino acid sequence of SEQ ID NO: 109;

(qqq) an α chain comprising the amino acid sequence of SEQ ID NO: 126;

(rrr) a β chain comprising the amino acid sequence of SEQ ID NO: 127;

(sss) an α chain comprising the amino acid sequence of SEQ ID NO: 110;

(ttt) a β chain comprising the amino acid sequence of SEQ ID NO: 111;

(uuu) an α chain comprising the amino acid sequence of SEQ ID NO: 78;

(vvv) a β chain comprising the amino acid sequence of SEQ ID NO: 79;

(www) an α chain comprising the amino acid sequence of SEQ ID NO: 138;

(xxx) a β chain comprising the amino acid sequence of SEQ ID NO: 139;

(yyy) an α chain comprising the amino acid sequence of SEQ ID NO: 134;

(zzz) a β chain comprising the amino acid sequence of SEQ ID NO: 135;

(aaaa) an α chain comprising the amino acid sequence of SEQ ID NO: 140;

(bbbb) a β chain comprising the amino acid sequence of SEQ ID NO: 141;

(dddd) both (eee) and (fff); both (eee) and (hhh); both (fff) and (ggg); both (ggg) and (hhh); both (iii) and (jjj); both (iii) and (lll); both (jjj) and (kkk); or both (kkk) and (lll);

(eeee) both (mmm) and (nnn); both (mmm) and (ppp); both (nnn) and (ooo); both (ooo) and (ppp); both (qqq) and (rrr); both (qqq) and (ttt); both (rrr) and (sss); or both (sss) and (ttt); or

(ffff) both (uuu) and (vvv); both (uuu) and (xxx); both (vvv) and (www); both (www) and (xxx); both (yyy) and (zzz); both (yyy) and (bbbb); both (yyy) and (aaaa); or both (aaaa) and (bbbb).

6. An polypeptide comprising a functional portion of the TCR according to any one of claims 1-5, wherein the functional portion comprises the amino acid sequences of:

(a) all of SEQ ID NOs: 1-6,

(b) all of SEQ ID NOs: 31-36, or

(c) all of SEQ ID NOs: 64-69,

wherein the functional portion has antigenic specificity for a mutated human RAS amino acid sequence presented by an HLA-C molecule,

wherein the mutated human RAS amino acid sequence is a mutated human KRAS, a mutated human HRAS, or a mutated human NRAS amino acid sequence,

wherein the mutated human RAS amino acid sequence has a substitution of glycine at position 12 with valine, and

wherein position 12 is defined by reference to the wild-type human KRAS, wild-type human HRAS, or wild-type human NRAS protein, respectively.

7. The polypeptide according to claim 6, wherein the functional portion comprises:

(i) the amino acid sequence of SEQ ID NO: 7;

(ii) the amino acid sequence of SEQ ID NO: 8;

(iii) the amino acid sequence of SEQ ID NO: 90;

(iv) the amino acid sequence of SEQ ID NO: 91;

(v) the amino acid sequence of SEQ ID NO: 37;

(vi) the amino acid sequence of SEQ ID NO: 38;

(vii) the amino acid sequence of SEQ ID NO: 92;

(viii) the amino acid sequence of SEQ ID NO: 93;

(ix) the amino acid sequence of SEQ ID NO: 70;

(x) the amino acid sequence of SEQ ID NO: 71;

(xi) the amino acid sequence of SEQ ID NO: 132;

(xii) the amino acid sequence of SEQ ID NO: 133;

(xiii) the amino acid sequence of SEQ ID NO: 47;

(xiv) the amino acid sequence of SEQ ID NO: 48;

(xv) the amino acid sequence of SEQ ID NO: 94;

(xvi) the amino acid sequence of SEQ ID NO: 85;

(xvii) the amino acid sequence of SEQ ID NO: 95;

(xviii) the amino acid sequence of SEQ ID NO: 49;

(xix) the amino acid sequence of SEQ ID NO: 50;

(xx) the amino acid sequence of SEQ ID NO: 96;

(xxi) the amino acid sequence of SEQ ID NO: 87;

(xxii) the amino acid sequence of SEQ ID NO: 97;

(xxiii) the amino acid sequence of SEQ ID NO: 72;

(xxvi) the amino acid sequence of SEQ ID NO: 73;

(xxv) the amino acid sequence of SEQ ID NO: 88;

(xxvi) the amino acid sequence of SEQ ID NO: 89; or

(xxvii) both (i) and (ii), both (i) and (iv), both (ii) and (iii), both (iii) and (iv), both (v) and (vi), both (v) and (viii), both (vi) and (vii), both (vii) and (viii), both (ix) and (x), both (ix) and (xii), both (x) and (xi), both (xi) and (xii), both (xiii) and (xiv), both (xiii) and (xvi), both (xiii) and (xvii), both (xiv) and (xv), both (xv) and (xvi), both (xv) and (xvii), both (xviii) and (xix), both (xviii) and (xxi), both (xviii) and (xxii), both (xix) and (xx), both (xx) and (xxi), both (xx) and (xxii), both (xxiii) and (xxiv), both (xxiii) and (xxvi), both (xxiv) and (xxv), or both (xxv) and (xxvi).

8. The polypeptide according to claim 6 or 7, further comprising:

(a) the amino acid sequence of SEQ ID NO: 17, wherein:

(i) X at position 48 of SEQ ID NO: 17 is Thr or Cys;

(ii) X at position 112 of SEQ ID NO: 17 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 of SEQ ID NO: 17 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 115 of SEQ ID NO: 17 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) the amino acid sequence of SEQ ID NO: 18, wherein X at position 57 of SEQ ID NO: 18 is Ser or Cys; or

(c) both (a) and (b).

9. The polypeptide according to any one of claims 6-8, comprising:

(a) an α chain comprising the amino acid sequence of SEQ ID NO: 21, wherein:

(i) X at position 180 of SEQ ID NO: 21 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 21 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 21 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 21 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a β chain comprising the amino acid sequence of SEQ ID NO: 22, wherein X at position 190 of SEQ ID NO: 22 is Ser or Cys;

(c) an α chain comprising the amino acid sequence of SEQ ID NO: 100, wherein:

(i) X at position 180 of SEQ ID NO: 100 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 100 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 100 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 100 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(d) a β chain comprising the amino acid sequence of SEQ ID NO: 101, wherein X at position 190 of SEQ ID NO: 101 is Ser or Cys;

(e) an α chain comprising the amino acid sequence of SEQ ID NO: 41, wherein:

(i) X at position 181 of SEQ ID NO: 41 is Thr or Cys;

(ii) X at position 245 of SEQ ID NO: 41 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 247 of SEQ ID NO: 41 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 248 of SEQ ID NO: 41 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(f) a β chain comprising the amino acid sequence of SEQ ID NO: 42, wherein X at position 195 of SEQ ID NO: 42 is Ser or Cys;

(g) an α chain comprising the amino acid sequence of SEQ ID NO: 106, wherein:

(i) X at position 181 of SEQ ID NO: 106 is Thr or Cys;

(ii) X at position 245 of SEQ ID NO: 106 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 247 of SEQ ID NO: 106 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 248 of SEQ ID NO: 106 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(h) a β chain comprising the amino acid sequence of SEQ ID NO: 107, wherein X at position 195 of SEQ ID NO: 107 is Ser or Cys;

(i) an α chain comprising the amino acid sequence of SEQ ID NO: 74, wherein:

(i) X at position 180 of SEQ ID NO: 74 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 74 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 74 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 74 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(j) a β chain comprising the amino acid sequence of SEQ ID NO: 75, wherein X at position 187 of SEQ ID NO: 75 is Ser or Cys;

(k) an α chain comprising the amino acid sequence of SEQ ID NO: 136, wherein:

(i) X at position 180 of SEQ ID NO: 136 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 136 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 136 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 136 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(l) a β chain comprising the amino acid sequence of SEQ ID NO: 137, wherein X at position 187 of SEQ ID NO: 75 is Ser or Cys;

(m) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d);

(n) both (e) and (f); both (e) and h); both (f) and (g); or both (g) and (h);

(n) both (i) and (j); both (i) and l); both (j) and (k); or both (k) and (l);

(o) an α chain comprising the amino acid sequence of SEQ ID NO: 55, wherein:

(i) X at position 160 of SEQ ID NO: 55 is Thr or Cys;

(ii) X at position 224 of SEQ ID NO: 55 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 226 of SEQ ID NO: 55 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 227 of SEQ ID NO: 55 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(p) a β chain comprising the amino acid sequence of SEQ ID NO: 56, wherein X at position 168 of SEQ ID NO: 56 is Ser or Cys;

(q) an α chain comprising the amino acid sequence of SEQ ID NO: 112, wherein:

(i) X at position 159 of SEQ ID NO: 112 is Thr or Cys;

(ii) X at position 223 of SEQ ID NO: 112 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 225 of SEQ ID NO: 112 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 226 of SEQ ID NO: 112 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(r) a β chain comprising the amino acid sequence of SEQ ID NO: 113, wherein X at position 173 of SEQ ID NO: 113 is Ser or Cys;

(s) an α chain comprising the amino acid sequence of SEQ ID NO: 57, wherein:

(i) X at position 160 of SEQ ID NO: 57 is Thr or Cys;

(ii) X at position 224 of SEQ ID NO: 57 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 226 of SEQ ID NO: 57 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 227 of SEQ ID NO: 57 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(t) a β chain comprising the amino acid sequence of SEQ ID NO: 58, wherein X at position 173 of SEQ ID NO: 58 is Ser or Cys;

(u) an α chain comprising the amino acid sequence of SEQ ID NO: 118, wherein:

(i) X at position 161 of SEQ ID NO: 118 is Thr or Cys;

(ii) X at position 225 of SEQ ID NO: 118 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 227 of SEQ ID NO: 118 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 228 of SEQ ID NO: 118 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(v) a β chain comprising the amino acid sequence of SEQ ID NO: 119, wherein X at position 178 of SEQ ID NO: 119 is Ser or Cys;

(w) an α chain comprising the amino acid sequence of SEQ ID NO: 76, wherein:

(i) X at position 159 of SEQ ID NO: 76 is Thr or Cys;

(ii) X at position 223 of SEQ ID NO: 76 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 225 of SEQ ID NO: 76 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 226 of SEQ ID NO: 76 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(x) a β chain comprising the amino acid sequence of SEQ ID NO: 77, wherein X at position 168 of SEQ ID NO: 77 is Ser or Cys;

(y) an α chain comprising the amino acid sequence of SEQ ID NO: 144, wherein:

(i) X at position 160 of SEQ ID NO: 144 is Thr or Cys;

(ii) X at position 224 of SEQ ID NO: 144 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 226 of SEQ ID NO: 144 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 227 of SEQ ID NO: 144 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(z) a β chain comprising the amino acid sequence of SEQ ID NO: 145, wherein X at position 166 of SEQ ID NO: 145 is Ser or Cys;

(aa) both (o) and (p); or both (q) and (r);

(bb) both (s) and (t); or both (u) and (v);

(cc) both (w) and (x); or both (y) and (z);

(dd) an α chain comprising the amino acid sequence of SEQ ID NO: 51;

(ee) a β chain comprising the amino acid sequence of SEQ ID NO: 52;

(ff) an α chain comprising the amino acid sequence of SEQ ID NO: 114;

(gg) a β chain comprising the amino acid sequence of SEQ ID NO: 115;

(hh) an α chain comprising the amino acid sequence of SEQ ID NO: 128;

(ii) a β chain comprising the amino acid sequence of SEQ ID NO: 129;

(jj) an α chain comprising the amino acid sequence of SEQ ID NO: 116;

(kk) a β chain comprising the amino acid sequence of SEQ ID NO: 117;

(ll) an α chain comprising the amino acid sequence of SEQ ID NO: 53;

(mm) a β chain comprising the amino acid sequence of SEQ ID NO: 54;

(nn) an α chain comprising the amino acid sequence of SEQ ID NO: 120;

(oo) a β chain comprising the amino acid sequence of SEQ ID NO: 121;

(pp) an α chain comprising the amino acid sequence of SEQ ID NO: 130;

(qq) a β chain comprising the amino acid sequence of SEQ ID NO: 131;

(rr) an α chain comprising the amino acid sequence of SEQ ID NO: 122;

(ss) a β chain comprising the amino acid sequence of SEQ ID NO: 123;

(tt) an α chain comprising the amino acid sequence of SEQ ID NO: 80;

(uu) a β chain comprising the amino acid sequence of SEQ ID NO: 81;

(vv) an α chain comprising the amino acid sequence of SEQ ID NO: 146;

(ww) a β chain comprising the amino acid sequence of SEQ ID NO: 146;

(xx) an α chain comprising the amino acid sequence of SEQ ID NO: 142;

(yy) a β chain comprising the amino acid sequence of SEQ ID NO: 143;

(zz) an α chain comprising the amino acid sequence of SEQ ID NO: 148;

(aaa) a β chain comprising the amino acid sequence of SEQ ID NO: 149;

(bbb) both (dd) and (ee); both (ff) and (gg); both (hh) and (ii); or both (jj) and (kk);

(ccc) both (ll) and (mm); both (nn) and (oo); both (pp) and (qq); or both (rr) and (ss);

(ddd) both (tt) and (uu); both (vv) and (ww); both (xx) and (yy); or both (zz) and (aaa);

(eee) an α chain comprising the amino acid sequence of SEQ ID NO: 23;

(fff) a β chain comprising the amino acid sequence of SEQ ID NO: 24;

(ggg) an α chain comprising the amino acid sequence of SEQ ID NO: 102;

(hhh) a β chain comprising the amino acid sequence of SEQ ID NO: 103;

(iii) an α chain comprising the amino acid sequence of SEQ ID NO: 124;

(jjj) a β chain comprising the amino acid sequence of SEQ ID NO: 125;

(kkk) an α chain comprising the amino acid sequence of SEQ ID NO: 104;

(lll) a β chain comprising the amino acid sequence of SEQ ID NO: 105;

(mmm) an α chain comprising the amino acid sequence of SEQ ID NO: 39;

(nnn) a β chain comprising the amino acid sequence of SEQ ID NO: 40;

(ooo) an α chain comprising the amino acid sequence of SEQ ID NO: 108;

(ppp) a β chain comprising the amino acid sequence of SEQ ID NO: 109;

(qqq) an α chain comprising the amino acid sequence of SEQ ID NO: 126;

(rrr) a β chain comprising the amino acid sequence of SEQ ID NO: 127;

(sss) an α chain comprising the amino acid sequence of SEQ ID NO: 110;

(ttt) a β chain comprising the amino acid sequence of SEQ ID NO: 111;

(uuu) an α chain comprising the amino acid sequence of SEQ ID NO: 78;

(vvv) a β chain comprising the amino acid sequence of SEQ ID NO: 79;

(www) an α chain comprising the amino acid sequence of SEQ ID NO: 138;

(xxx) a β chain comprising the amino acid sequence of SEQ ID NO: 139;

(yyy) an α chain comprising the amino acid sequence of SEQ ID NO: 134;

(zzz) a β chain comprising the amino acid sequence of SEQ ID NO: 135;

(aaaa) an α chain comprising the amino acid sequence of SEQ ID NO: 140;

(bbbb) a β chain comprising the amino acid sequence of SEQ ID NO: 141;

(dddd) both (eee) and (fff); both (eee) and (hhh); both (fff) and (ggg); both (ggg) and (hhh); both (iii) and (jjj); both (iii) and (lll); both (jjj) and (kkk); or both (kkk) and (lll);

(eeee) both (mmm) and (nnn); both (mmm) and (ppp); both (nnn) and (ooo); both (ooo) and (ppp); both (qqq) and (rrr); both (qqq) and (ttt); both (rrr) and (sss); or both (sss) and (ttt); or

(ffff) both (uuu) and (vvv); both (uuu) and (xxx); both (vvv) and (www); both (www) and (xxx); both (yyy) and (zzz); both (yyy) and (bbbb); both (yyy) and (aaaa); or both (aaaa) and (bbbb).

10. A protein comprising:

(a) a first polypeptide chain comprising the amino acid sequences of SEQ ID NOs: 1-3 and a second polypeptide chain comprising the amino acid sequences of SEQ ID NOs: 4-6;

(b) a first polypeptide chain comprising the amino acid sequences of SEQ ID NOs: 31-33 and a second polypeptide chain comprising the amino acid sequences of SEQ ID NOs: 34-36; or

(c) a first polypeptide chain comprising the amino acid sequences of SEQ ID NOs: 64-66 and a second polypeptide chain comprising the amino acid sequences of SEQ ID NOs: 67-69,

wherein the protein has antigenic specificity for a mutated human RAS amino acid sequence presented by an HLA-C molecule,

wherein the mutated human RAS amino acid sequence is a mutated human KRAS, a mutated human HRAS, or a mutated human NRAS amino acid sequence,

wherein the mutated human RAS amino acid sequence has a substitution of glycine at position 12 with valine, and

wherein position 12 is defined by reference to the wild-type human KRAS, wild-type human HRAS, or wild-type human NRAS protein, respectively.

11. The protein according to claim 10, comprising:

(i) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 7;

(ii) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 8;

(iii) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 90;

(iv) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 91;

(v) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 37;

(vi) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 38;

(vii) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 92;

(viii) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 70;

(x) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 71;

(xi) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 132;

(xii) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 133;

(xiii) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 47;

(xiv) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 48;

(xv) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 94;

(xvi) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 85;

(xvii) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 95;

(xviii) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 49;

(xix) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 50;

(xx) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 96;

(xxi) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 87;

(xxii) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 97;

(xxiii) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 72;

(xxvi) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 73;

(xxv) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 88;

(xxvi) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 89; or

(xxvii) both (i) and (ii), both (i) and (iv), both (ii) and (iii), both (iii) and (iv), both (v) and (vi), both (v) and (viii), both (vi) and (vii), both (vii) and (viii), both (ix) and (x), both (ix) and (xii), both (x) and (xi), both (xi) and (xii), both (xiii) and (xiv), both (xiii) and (xvi), both (xiii) and (xvii), both (xiv) and (xv), both (xv) and (xvi), both (xv) and (xvii), both (xviii) and (xix), both (xviii) and (xxi), both (xviii) and (xxii), both (xix) and (xx), both (xx) and (xxi), both (xx) and (xxii), both (xxiii) and (xxiv), both (xxiii) and (xxvi), both (xxiv) and (xxv), or both (xxv) and (xxvi).

12. The protein according to claim 10 or 11, further comprising:

(a) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 17, wherein:

(i) X at position 48 of SEQ ID NO: 17 is Thr or Cys;

(ii) X at position 112 of SEQ ID NO: 17 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 114 of SEQ ID NO: 17 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 115 of SEQ ID NO: 17 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 18, wherein X at position 57 of SEQ ID NO: 18 is Ser or Cys; or

(c) both (a) and (b).

13. The protein according to any one of claims 10-12, comprising:

(a) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 21, wherein:

(i) X at position 180 of SEQ ID NO: 21 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 21 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 21 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 21 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(b) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 22, wherein X at position 190 of SEQ ID NO: 22 is Ser or Cys;

(c) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 100, wherein:

(i) X at position 180 of SEQ ID NO: 100 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 100 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 100 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 100 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(d) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 101, wherein X at position 190 of SEQ ID NO: 101 is Ser or Cys;

(e) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 41, wherein:

(i) X at position 181 of SEQ ID NO: 41 is Thr or Cys;

(ii) X at position 245 of SEQ ID NO: 41 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 247 of SEQ ID NO: 41 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 248 of SEQ ID NO: 41 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(f) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 42, wherein X at position 195 of SEQ ID NO: 42 is Ser or Cys;

(g) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 106, wherein:

(i) X at position 181 of SEQ ID NO: 106 is Thr or Cys;

(ii) X at position 245 of SEQ ID NO: 106 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 247 of SEQ ID NO: 106 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 248 of SEQ ID NO: 106 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(h) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 107, wherein X at position 195 of SEQ ID NO: 107 is Ser or Cys;

(i) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 74, wherein:

(i) X at position 180 of SEQ ID NO: 74 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 74 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 74 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 74 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(j) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 75, wherein X at position 187 of SEQ ID NO: 75 is Ser or Cys;

(k) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 136, wherein:

(i) X at position 180 of SEQ ID NO: 136 is Thr or Cys;

(ii) X at position 244 of SEQ ID NO: 136 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 246 of SEQ ID NO: 136 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 247 of SEQ ID NO: 136 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(l) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 137, wherein X at position 187 of SEQ ID NO: 75 is Ser or Cys;

(m) both (a) and (b); both (a) and (d); both (b) and (c); or both (c) and (d);

(n) both (e) and (f); both (e) and h); both (f) and (g); or both (g) and (h);

(n) both (i) and (j); both (i) and l); both (j) and (k); or both (k) and (l);

(o) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 55, wherein:

(i) X at position 160 of SEQ ID NO: 55 is Thr or Cys;

(ii) X at position 224 of SEQ ID NO: 55 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 226 of SEQ ID NO: 55 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 227 of SEQ ID NO: 55 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(p) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 56, wherein X at position 168 of SEQ ID NO: 56 is Ser or Cys;

(q) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 112, wherein:

(i) X at position 159 of SEQ ID NO: 112 is Thr or Cys;

(ii) X at position 223 of SEQ ID NO: 112 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 225 of SEQ ID NO: 112 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 226 of SEQ ID NO: 112 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(r) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 113, wherein X at position 173 of SEQ ID NO: 113 is Ser or Cys;

(s) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 57, wherein:

(i) X at position 160 of SEQ ID NO: 57 is Thr or Cys;

(ii) X at position 224 of SEQ ID NO: 57 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 226 of SEQ ID NO: 57 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 227 of SEQ ID NO: 57 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(t) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 58, wherein X at position 173 of SEQ ID NO: 58 is Ser or Cys;

(u) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 118, wherein:

(i) X at position 161 of SEQ ID NO: 118 is Thr or Cys;

(ii) X at position 225 of SEQ ID NO: 118 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 227 of SEQ ID NO: 118 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 228 of SEQ ID NO: 118 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(v) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 119, wherein X at position 178 of SEQ ID NO: 119 is Ser or Cys;

(w) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 76, wherein:

(i) X at position 159 of SEQ ID NO: 76 is Thr or Cys;

(ii) X at position 223 of SEQ ID NO: 76 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 225 of SEQ ID NO: 76 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 226 of SEQ ID NO: 76 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(x) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 77, wherein X at position 168 of SEQ ID NO: 77 is Ser or Cys;

(y) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 144, wherein:

(i) X at position 160 of SEQ ID NO: 144 is Thr or Cys;

(ii) X at position 224 of SEQ ID NO: 144 is Ser, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(iii) X at position 226 of SEQ ID NO: 144 is Met, Ala, Val, Leu, Ile, Pro, Phe, or Trp; and

(iv) X at position 227 of SEQ ID NO: 144 is Gly, Ala, Val, Leu, Ile, Pro, Phe, Met, or Trp;

(z) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 145, wherein X at position 166 of SEQ ID NO: 145 is Ser or Cys;

(aa) both (o) and (p); or both (q) and (r);

(bb) both (s) and (t); or both (u) and (v);

(cc) both (w) and (x); or both (y) and (z);

(dd) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 51;

(ee) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 52;

(ff) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 114;

(gg) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 115;

(hh) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 128;

(ii) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 129;

(jj) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 116;

(kk) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 117;

(ll) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 53;

(mm) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 54;

(nn) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 120;

(oo) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 121;

(pp) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 130;

(qq) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 131;

(rr) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 122;

(ss) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 123;

(tt) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 80;

(uu) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 81;

(vv) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 146;

(ww) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 146;

(xx) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 142;

(yy) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 143;

(zz) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 148;

(aaa) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 149;

(bbb) both (dd) and (ee); both (ff) and (gg); both (hh) and (ii); or both (jj) and (kk);

(ccc) both (ll) and (mm); both (nn) and (oo); both (pp) and (qq); or both (rr) and (ss);

(ddd) both (tt) and (uu); both (vv) and (ww); both (xx) and (yy); or both (zz) and (aaa);

(eee) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 23;

(fff) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 24;

(ggg) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 102;

(hhh) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 103;

(iii) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 124;

(jjj) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 125;

(kkk) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 104;

(lll) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 105;

(mmm) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 39;

(nnn) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 40;

(ooo) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 108;

(ppp) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 109;

(qqq) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 126;

(rrr) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 127;

(sss) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 110;

(ttt) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 111;

(uuu) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 78;

(vvv) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 79;

(www) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 138;

(xxx) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 139;

(yyy) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 134;

(zzz) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 135;

(aaaa) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO: 140;

(bbbb) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO: 141;

(dddd) both (eee) and (fff); both (eee) and (hhh); both (fff) and (ggg); both (ggg) and (hhh); both (iii) and (jjj); both (iii) and (lll); both (jjj) and (kkk); or both (kkk) and (lll);

(eeee) both (mmm) and (nnn); both (mmm) and (ppp); both (nnn) and (ooo); both (ooo) and (ppp); both (qqq) and (rrr); both (qqq) and (ttt); both (rrr) and (sss); or both (sss) and (ttt); or

(ffff) both (uuu) and (vvv); both (uuu) and (xxx); both (vvv) and (www); both (www) and (xxx); both (yyy) and (zzz); both (yyy) and (bbbb); both (yyy) and (aaaa); or both (aaaa) and (bbbb).

14. An nucleic acid comprising a nucleotide sequence encoding the TCR according to any one of claims 1-5, the polypeptide according to any one of claims 6-9, or the protein according to any one of claims 10-13.

15. A nucleic acid comprising, from 5’ to 3’, a first nucleic acid sequence and a second nucleotide sequence, wherein the first and second nucleotide sequence, respectively, encode the amino sequences of SEQ ID NOs: 7 and 8; 7 and 91; 90 and 8; 90 and 91; 8 and 7; 91 and 7; 8 and 90; 91 and 90; 37 and 38; 37 and 93; 92 and 38; 92 and 93; 38 and 37; 93 and 37; 38 and 92; 93 and 92; 70 and 71; 70 and 133; 132 and 71; 132 and 133; 71 and 70; 133 and 70; 71 and 132; 133 and 132; 23 and 24; 23 and 103; 102 and 24; 102 and 103; 24 and 23; 103 and 23; 24 and 102; 103 and 102; 39 and 40; 39 and 109; 108 and 40; 108 and 109; 40 and 39; 109 and 39; 40 and 108; 109 and 108; 78 and 79; 78 and 139; 138 and 79; 138 and 139; 79 and 78; 139 and 78; 79 and 138; 139 and 138; 21 and 22; 21 and 101; 100 and 22; 100 and 101; 22 and 21; 101 and 21; 22 and 100; 101 and 100; 41 and 42; 41 and 107; 106 and 42; 106 and 107; 42 and 41; 107 and 41; 42 and 106; 107 and 106; 74 and 75; 74 and 101; 100 and 75, 100 and 101; 75 and 74; 101 and 74; 75 and 100; 101 and 100; 124 and 125; 124 and 105; 104 and 125; 104 and 105; 125 and 124; 105 and 124; 125 and 104; 105 and 104; 126 and 127; 126 and 111; 110 and 127; 110 and 111; 127 and 126; 111 and 126; 127 and 110; 111 and 110; 134 and 135; 140 and 135; 134 and 141; 140 and 141; 135 and 134; 135 and 140; 141 and 134; 141 and 140; 47 and 48; 48 and 47; 49 and 50; 50 and 49; 72 and 73; 73 and 72; 94 and 95; 95 and 94; 94 and 85; 85 and 94; 96 and 97; 97 and 96; 96 and 87; 87 and 96; 88 and 89; 89 and 88; 51 and 52; 52 and 51; 53 and 54; 54 and 53; 80 and 81; 81 and 80; 55 and 56; 56 and 55; 57 and 58; 58 and 57; 76 and 77; 77 and 76; 128 and 129; 129 and 128; 130 and 131; 131 and 130; 142 and 143; 143 and 142; 112 and 113; 113 and 112;

118 and 119; 119 and 118; 144 and 145; 145 and 144; 114 and 115; 115 and 114; 120 and 121; 121 and 120; 146 and 147; 147 and 146; 116 and 117; 117 and 116; 122 and 123; 123 and 122; 148 and 149; 149 and 148; 150 and 151; 151 and 150; 154 and 155; 155 and 154; 152 and 153; 153 and 152; 156 and 157; 157 and 156; 160 and 161; 161 and 160; 158 and 159; or 159 and 158.

16. A recombinant expression vector comprising the nucleic acid according to claim 14 or 15.

17. The recombinant expression vector according to claim 16, which is a transposon or a lentiviral vector.

18. A TCR, polypeptide, or protein encoded by the nucleic acid according to claim 14or 15 or the vector according to claim 16 or 17.

19. A host cell comprising the nucleic acid according to claim 14 or 15 or the recombinant expression vector according to claim 16 or 17.

20. The host cell according to claim 19, wherein the cell is selected from the group consisting of a T cell, a natural killer T (NKT) cell, an invariant natural killer T (iNKT) cell, and a natural killer (NK) cell.

21. A population of cells comprising the host cell according to claim 19 or 20.

22. A pharmaceutical composition comprising (a) the TCR according to any one of claims 1-5 or 18, the polypeptide according to any one of claims 6-9 or 18, or the protein according to any one of claims 10-13 or 18, the nucleic acid according to claim 14 or 15, the recombinant expression vector according to claim 16 or 17, the host cell according to claim 19 or 20, or the population of cells according to claim 21 and (b) a pharmaceutically acceptable carrier.

23. Use of the TCR according to any one of claims 1-5 or 18, the polypeptide according to any one of claims 6-9 or 18, or the protein according to any one of claims 10-13 or 18, the recombinant expression vector according to claim 16 or 17, wherein the recombinant expression vector is suitable for expression by the host cell of claim 20, the host cell according to claim 20, wherein the recombinant expression vector comprised by the host cell is suitable for expression by the host cell of claim 20, a population of cells comprising the host cell, or a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the TCR, polypeptide, protein, recombinant expression vector, host cell, or population of cells, in the manufacture of a medicament for the treatment of cancer in a mammal.

24. The use according to claim 23, wherein the cancer expresses a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine,

wherein the mutated human RAS amino acid sequence is a mutated human Kirsten rat sarcoma viral oncogene homolog (KRAS), a mutated human Harvey rat sarcoma viral oncogene homolog (HRAS), or a mutated human Neuroblastoma rat sarcoma viral oncogene homolog (NRAS) amino acid sequence, and

wherein position 12 is defined by reference to the wild-type human KRAS, wild-type human HRAS, or wild-type human NRAS protein, respectively.